• Something wrong with this record ?

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples

L. Alemany, M. Saunier, L. Tinoco, B. Quirós, I. Alvarado-Cabrero, M. Alejo, EA. Joura, P. Maldonado, J. Klaustermeier, J. Salmerón, C. Bergeron, KU. Petry, N. Guimerà, O. Clavero, R. Murillo, C. Clavel, V. Wain, DT. Geraets, R. Jach, P. Cross,...

. 2014 ; 50 (16) : 2846-54.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15007944

AIM: This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. METHODS: We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA25 system (version 1). A subset of 146 vaginal cancers was tested for p16(INK4a) expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. RESULTS: HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16(INK4a) overexpression was found in 87% of HPV DNA positive vaginal cancer cases. CONCLUSIONS: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.

3rd Faculty of Medicine and Faculty Hospital King's Wineyards Prague Czech Republic

Cancer Institute of Colombia Colombia

Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva CIESAR Hospital General San Juan de Dios HGSJDD Guatemala Guatemala

Centro de Oncología Preventiva Universidad de Chile Santiago Chile

CHU Reims Hopital Maison Blanche Laboratoire Pol Bouin Reims France

CIBER en Epidemiología y Salud Pública Spain

DDL Diagnostic Laboratory Rijswijk The Netherlands

Department of Gynaecology and Obstetrics Medical University of Vienna Comprehensive Cancer Center Vienna Austria

Faculty of Medicine Eduardo Mondlane University and Maputo Central Hospital Maputo Mozambique

German Cancer Research Center Heidelberg Germany

Hospital General de L'Hospitalet Barcelona Spain

Hospital Oncológico Quito Ecuador

Hospital Universitari de Bellvitge Barcelona Spain

INSERM UMR S903 Reims France

Instituto de Ginecologia da Universidad Federal Do Rio de Janeiro UFRJ Rio de Janeiro Brazil

Instituto Nacional de Cancerología Bogotá Colombia

Instituto Potosino de Investigación Científica y Tecnológica AC San Luis Potosí Mexico

Jagiellonian University Medical College Krakow Poland

Klinikum Wolfsburg Wolfsburg Germany

Laboratoire Cerba Department de Pathologie Paris France

Laboratorio de Anatomia Patológica del Hospital de la Mujer Montevideo Uruguay

Manchester Royal Infirmary Manchester United Kingdom

Medical University of Lublin Lublin Poland

Mexican Oncology Hospital IMSS Mexico DF Mexico

National Cancer Center Seoul South Korea

Queen Elizabeth Hospital Sheriff Hill UK

Unit of Infections and Cancer Cancer Epidemiology Research Program Catalan Institute of Oncology IDIBELL L'Hospitalet de Llobregat Barcelona Spain

WestMead Hospital Sydney Australia

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15007944
003      
CZ-PrNML
005      
20150324113009.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2014.07.018 $2 doi
035    __
$a (PubMed)25155250
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Alemany, L $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: lalemany@iconcologia.net. $7 gn_A_00003817
245    10
$a Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples / $c L. Alemany, M. Saunier, L. Tinoco, B. Quirós, I. Alvarado-Cabrero, M. Alejo, EA. Joura, P. Maldonado, J. Klaustermeier, J. Salmerón, C. Bergeron, KU. Petry, N. Guimerà, O. Clavero, R. Murillo, C. Clavel, V. Wain, DT. Geraets, R. Jach, P. Cross, C. Carrilho, C. Molina, HR. Shin, V. Mandys, AM. Nowakowski, A. Vidal, L. Lombardi, H. Kitchener, AR. Sica, C. Magaña-León, M. Pawlita, W. Quint, IG. Bravo, N. Muñoz, S. de Sanjosé, FX. Bosch, . ,
520    9_
$a AIM: This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. METHODS: We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA25 system (version 1). A subset of 146 vaginal cancers was tested for p16(INK4a) expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. RESULTS: HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16(INK4a) overexpression was found in 87% of HPV DNA positive vaginal cancer cases. CONCLUSIONS: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.
650    _2
$a senioři $7 D000368
650    _2
$a spinocelulární karcinom $x komplikace $x epidemiologie $x virologie $7 D002294
650    _2
$a průřezové studie $7 D003430
650    _2
$a inhibitor p16 cyklin-dependentní kinasy $x metabolismus $7 D019941
650    _2
$a DNA virů $x analýza $7 D004279
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidský papilomavirus 16 $x izolace a purifikace $7 D052162
650    _2
$a lidé $7 D006801
650    _2
$a imunoenzymatické techniky $7 D007124
650    _2
$a mezinárodní spolupráce $7 D007391
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Papillomaviridae $x izolace a purifikace $7 D027383
650    _2
$a infekce papilomavirem $x komplikace $x epidemiologie $x virologie $7 D030361
650    _2
$a Poissonovo rozdělení $7 D016012
650    _2
$a prekancerózy $x epidemiologie $x virologie $7 D011230
650    _2
$a prevalence $7 D015995
650    _2
$a regresní analýza $7 D012044
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory vaginy $x komplikace $x epidemiologie $x virologie $7 D014625
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Saunier, M $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Tinoco, L $u Hospital Oncológico, Quito, Ecuador.
700    1_
$a Quirós, B $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Alvarado-Cabrero, I $u Mexican Oncology Hospital, IMSS, Mexico, DF, Mexico. $7 gn_A_00005079
700    1_
$a Alejo, M $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital General de L'Hospitalet, Barcelona, Spain. $7 gn_A_00003712
700    1_
$a Joura, E A $u Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
700    1_
$a Maldonado, P $u Instituto de Ginecologia da Universidad Federal Do Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil.
700    1_
$a Klaustermeier, J $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.
700    1_
$a Salmerón, J $u Mexican Oncology Hospital, IMSS, Mexico, DF, Mexico.
700    1_
$a Bergeron, C $u Laboratoire Cerba, Department de Pathologie, Paris, France.
700    1_
$a Petry, K U $u Klinikum Wolfsburg, Wolfsburg, Germany.
700    1_
$a Guimerà, N $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
700    1_
$a Clavero, O $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Murillo, R $u Instituto Nacional de Cancerología, Bogotá, Colombia.
700    1_
$a Clavel, C $u CHU Reims, Hopital Maison Blanche, Laboratoire Pol Bouin, Reims, France; INSERM UMR-S903, Reims, France.
700    1_
$a Wain, V $u WestMead Hospital, Sydney, Australia.
700    1_
$a Geraets, D T $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
700    1_
$a Jach, R $u Jagiellonian University Medical College, Krakow, Poland.
700    1_
$a Cross, P $u Queen Elizabeth Hospital, Sheriff Hill, UK.
700    1_
$a Carrilho, C $u Faculty of Medicine, Eduardo Mondlane University and Maputo Central Hospital, Maputo, Mozambique.
700    1_
$a Molina, C $u Centro de Oncología Preventiva, Universidad de Chile, Santiago, Chile.
700    1_
$a Shin, H R $u National Cancer Center, Seoul, South Korea.
700    1_
$a Mandys, V $u Third Faculty of Medicine and Faculty Hospital King's Wineyards, Prague, Czech Republic.
700    1_
$a Nowakowski, A M $u Medical University of Lublin, Lublin, Poland.
700    1_
$a Vidal, A $u Hospital Universitari de Bellvitge, Barcelona, Spain.
700    1_
$a Lombardi, L $u Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva - CIESAR, Hospital General San Juan de Dios - HGSJDD, Guatemala, Guatemala.
700    1_
$a Kitchener, H $u Manchester Royal Infirmary, Manchester, United Kingdom.
700    1_
$a Sica, A R $u Laboratorio de Anatomia Patológica del Hospital de la Mujer, Montevideo, Uruguay.
700    1_
$a Magaña-León, C $u Instituto Potosino de Investigación Científica y Tecnológica, AC (IPICYT), San Luis Potosí, Mexico.
700    1_
$a Pawlita, M $u German Cancer Research Center (DKFZ), Heidelberg, Germany.
700    1_
$a Quint, W $u DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
700    1_
$a Bravo, I G $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Muñoz, N $u Cancer Institute of Colombia, Colombia.
700    1_
$a de Sanjosé, S $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.
700    1_
$a Bosch, F X $u Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a ,
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England 1990) $x 1879-0852 $g Roč. 50, č. 16 (2014), s. 2846-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25155250 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150324113257 $b ABA008
999    __
$a ok $b bmc $g 1065217 $s 890744
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 50 $c 16 $d 2846-54 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20150306

Find record

Citation metrics

Archiving options